Categories AlphaGraphs, Earnings, Technology

Applied Materials’ stock dips on weak outlook

Applied Materials (AMAT) reported better-than-expected revenue and earnings for the first quarter of 2019 but the stock inched down 1.7% during aftermarket hours on Thursday as outlook fell short of expectations.

Net sales fell 11% year-over-year to $3.75 billion. GAAP net income improved to $771 million, or $0.80 per share, from $165 million, or $0.15 per share, in the prior-year period. On an adjusted basis, net income dropped 33% to $779 million while EPS fell 25% to $0.81.

Applied Materials first quarter 2019 earnings infographic
Applied Materials Q1 2019 Earnings Infographic

Gary Dickerson, President and CEO, said “Applied Materials delivered solid first quarter results in a challenging business environment. As we navigate the current market dynamics, we remain highly optimistic about the long term and are investing in new technology, products and capabilities that position the company to play a bigger and broader role in the industry’s future.”

During the quarter, sales declined in the Semiconductor Systems segment while in the Applied Global Services and the Display and Adjacent Markets segments, sales rose compared to the prior-year period.

The company delivered sales increases across all its major geographies except for Korea, Taiwan and Southeast Asia which posted declines. 26% of the sales came from China.

For the second quarter of 2019, the company expects net sales to be $3.33 billion to $3.63 billion. Adjusted EPS is expected to be $0.62 to $0.70.

Applied Materials returned $942 million to shareholders including $750 million in share repurchases and dividends of $192 million.

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Biogen (BIIB) stock research summary | Q3 2021

Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of

Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings

Goldman Sachs (GS) stock research summary | Q3 2021

Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top